Ignite Creation Date:
2024-05-05 @ 4:41 PM
Last Modification Date:
2024-10-26 @ 9:22 AM
Study NCT ID:
NCT00290004
Status:
COMPLETED
Last Update Posted:
2008-09-11
First Post:
2006-02-08
Brief Title:
Study of Weekly Motexafin Gadolinium MGd for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Sponsor:
Pharmacyclics LLC
Organization:
Pharmacyclics LLC
Study Overview
Official Title:
Phase III Trial of Weekly Motexafin Gadolinium MGd for Patients With Refractory or Relapsed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Status:
COMPLETED
Status Verified Date:
2008-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary purpose of this study is to evaluate the safety toxicities dosage and response rate for an investigational drug motexafin gadolinium administered to patients with chronic lymphocytic leukemia or small lymphocytic lymphoma The secondary purpose of this study is to evaluate the clinical benefit rate the time it takes for a patients chronic lymphocytic leukemia or small lymphocytic lymphoma to worsen the duration of response and the time during which patients survive without chronic lymphocytic leukemia or small lymphocytic lymphoma worsening Additionally the patients response to motexafin gadolinium will be compared to the response of the patients cells in a laboratory to motexafin gadolinium
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None